Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 2Multiple Myeloma 2Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Rituximab 21Cyclophosphamide 15Etoposide 11Vincristine 9Prednisone 9Doxorubicin 8Cytarabine 8Filgrastim 7Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5Melphalan 5Dexamethasone 4Carmustine 4Bendamustine Hydrochloride 4loncastuximab tesirine 3ibrutinib 3Tacrolimus 3Stem Cell Transplantation 3Mycophenolic Acid 3Methotrexate 3Gemcitabine 3Calcium Dobesilate 3CT-P10 3Busulfan 3venetoclax 2sargramostim 2polatuzumab vedotin 2pembrolizumab 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Large B-Cell, Diffuse × Panobinostat × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡